This site uses cookies to measure how you use the website so it can be updated and improved based on your needs and also uses cookies to help remember the notifications you’ve seen, like this one, so that we don’t show them to you again. If you could also tell us a little bit about yourself, this information will help us understand how we can support you better and make this site even easier for you to use and navigate.

Effects of cilostazol on cognition and regional cerebral blood flow in patients with Alzheimer’s disease and cerebrovascular disease: a pilot study


Sakurai, Hirofumi, Hanyu, Haruo, Sato, Tomohiko, Kume, Kazumasa, Hirao, Kentaro, Kanetaka, Hidekazu, Iwamoto, Toshihiko


Geriatrics & Gerontology International, Volume: 13, No.: 1, Pages.: 90-97

Year of Publication



Aim: It remains unknown whether antiplatelet agents have a preventive effect on cognitive decline in patients with Alzheimer’s disease (AD). We investigated the effects of cilostazol, an antiplatelet agent and cyclic adenosine monophosphate phosphodiesterase 3 inhibitor, on cognition and regional cerebral blood flow (rCBF) in elderly patients with AD and cerebrovascular disease (CVD).; Methods: A total of 20 patients with AD and CVD were randomly assigned to a cilostazol group (n=11, 100 mg daily) or control group (n=9, aspirin 100 mg or clopidogrel 50 mg-75 mg daily) for 6 months.; Results: The cilostazol group did not show any statistically significant changes in cognitive function test scores, whereas the control group showed statistically significant cognitive decline on the Alzheimer’s Disease Assessment Scale-Cognitive Subscale (Japanese version), Revised Wechsler Memory Scale (logical memory-I) and Trail Making Test-A. Analysis of covariance of treatment effect revealed that the cilostazol group showed increased rCBF in the right anterior cingulate lobe compared with baseline, whereas the control group showed decreased rCBF in the left middle temporal gyrus compared with baseline.; Conclusion: These findings suggest that cilostazol might have a preventive effect on cognitive decline in patients with AD and CVD.; © 2012 Japan Geriatrics Society.

Bibtex Citation

@article{Sakurai_2012, doi = {10.1111/j.1447-0594.2012.00866.x}, url = {}, year = 2012, month = {jun}, publisher = {Wiley-Blackwell}, volume = {13}, number = {1}, pages = {90--97}, author = {Hirofumi Sakurai and Haruo Hanyu and Tomohiko Sato and Kazumasa Kume and Kentaro Hirao and Hidekazu Kanetaka and Toshihiko Iwamoto}, title = {Effects of cilostazol on cognition and regional cerebral blood flow in patients with Alzheimer{textquotesingle}s disease and cerebrovascular disease: A pilot study}, journal = {Geriatrics {&} Gerontology International} }


adenosine, aged, aged, 80 and over, agent, alzheimer disease, analogs derivatives, analysis of variance, and, antiplatelet, aspirin, cerebrovascular circulation, cerebrovascular disorders, cilostazol, cognition, cyclic, drug effects, drug therapy, female, humans, inhibitor, magnetic resonance imaging, male, monophosphate, neuroprotective agents, phosphodiesterase, physiopathology, platelet aggregation inhibitors, prospective studies, statistics nonparametric, tetrazoles, therapeutic use, ticlopidine, tomography xray computed, treatment outcome

Countries of Study


Types of Dementia

Alzheimer’s Disease

Types of Study

Randomised Controlled Trial

Type of Outcomes


Type of Interventions

Pharmaceutical Interventions

Pharmaceutical Interventions